Spots Global Cancer Trial Database for microsatellite stable
Every month we try and update this database with for microsatellite stable cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC | NCT03791398 | Metastatic Colo... | Dose level 1 ON... Dose level 2 ON... Dose level 3 ON... | 18 Years - | Brown University | |
| Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer | NCT04110093 | Colorectal Canc... Immunotherapy | Regorafenib and... | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | NCT02860546 | Refractory Meta... | TAS-102 nivolumab | 18 Years - | Taiho Oncology, Inc. | |
| Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | NCT03007407 | Colorectal Canc... | durvalumab Tremelimumab | 18 Years - | NSABP Foundation Inc | |
| SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer | NCT05576480 | Rectal Cancer Locally Advance... | Short-course ra... Penpulimab CAPEOX TME surgery | 18 Years - 75 Years | Ruijin Hospital | |
| Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer | NCT05160727 | Mismatch Repair... Colorectal Canc... Microsatellite ... | Tislelizumab Irinotecan radiotherapy | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | NCT04689347 | Metastatic Colo... | Bevacizumab Irinotecan Leucovorin 5Fluorouracil Temozolomide | 18 Years - 75 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial | NCT04721301 | Colorectal Canc... Pancreatic Canc... | Nivolumab plus ... | 18 Years - | University Hospital Heidelberg | |
| Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | NCT03711058 | Unresectable or... Colon Cancer | Copanlisib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC | NCT03791398 | Metastatic Colo... | Dose level 1 ON... Dose level 2 ON... Dose level 3 ON... | 18 Years - | Brown University | |
| Botensilimab and Balstilimab Optimization in Colorectal Cancer | NCT06268015 | Colorectal Canc... | Botensilimab Balstilimab Oxaliplatin Leucovorin Fluorouracil Bevacizumab Panitumumab | 18 Years - | Duke University | |
| Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial | NCT04721301 | Colorectal Canc... Pancreatic Canc... | Nivolumab plus ... | 18 Years - | University Hospital Heidelberg | |
| Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy | NCT05031975 | Colorectal Canc... | Irinotecan Temozolomide | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial | NCT04721301 | Colorectal Canc... Pancreatic Canc... | Nivolumab plus ... | 18 Years - | University Hospital Heidelberg | |
| Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer | NCT03102047 | Rectal Cancer | durvalumab | 18 Years - | NSABP Foundation Inc | |
| A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | NCT05572684 | Advanced or Met... Microsatellite ... Microsatellite ... Microsatellite ... Ovarian Cancer Gastric Cancer Colo-rectal Can... Esophageal Canc... Endometrial Can... Head Neck Cance... Cervical Cancer Lung Cancer | NC410 pembrolizumab | 18 Years - | NextCure, Inc. | |
| A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | NCT05167409 | Microsatellite ... | Evorpacept (ALX... Cetuximab Pembrolizumab | 18 Years - | University of Colorado, Denver | |
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer | NCT03832621 | Metastatic Colo... | Temozolomide Nivolumab Ipilimumab | 18 Years - 99 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | NCT05608044 | Metastatic Colo... | Botensilimab Balstilimab Standard of Car... | 18 Years - | Agenus Inc. | |
| Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer | NCT05730673 | CCR5 Microsatellite ... Metastatic Colorectal Canc... | 700mg leronlima... 80mg Regorafeni... 120mg Regorafen... 160 mg Regorafe... | 18 Years - | CytoDyn, Inc. | |
| Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC | NCT04145193 | Microsatellite-... | Standard of Car... E1 - mFOLFOX an... E2 - mFOLFOX6, ... E3 - mFOLFOX6, ... | 18 Years - 101 Years | MedImmune LLC | |
| Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer | NCT04194359 | Metastatic Colo... RAS Mutation Microsatellite ... | Sintilimab (IBI... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery | NCT03396926 | Microsatellite ... Mismatch Repair... Stage III Color... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... | Bevacizumab Capecitabine Laboratory Biom... Pembrolizumab | 18 Years - | University of California, San Francisco | |
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | NCT05608044 | Metastatic Colo... | Botensilimab Balstilimab Standard of Car... | 18 Years - | Agenus Inc. | |
| Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | NCT03711058 | Unresectable or... Colon Cancer | Copanlisib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer | NCT03983993 | Advanced Micros... Metastatic Micr... Microsatellite ... RAS Wild Type Stage IV Colore... MSI-H Colorecta... | Niraparib Panitumumab | 18 Years - | Emory University | |
| Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy | NCT05031975 | Colorectal Canc... | Irinotecan Temozolomide | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Botensilimab and Balstilimab Optimization in Colorectal Cancer | NCT06268015 | Colorectal Canc... | Botensilimab Balstilimab Oxaliplatin Leucovorin Fluorouracil Bevacizumab Panitumumab | 18 Years - | Duke University | |
| Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer | NCT05171660 | Colorectal Canc... | Sintilimab Inje... Control Test | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer | NCT04119830 | Metastatic Colo... Microsatellite ... Mismatch Repair... Refractory Colo... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... | Pembrolizumab Questionnaire A... Rintatolimod | 18 Years - | Roswell Park Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
